Form 4: CONMED Director Mark Kaye Receives Equity Compensation Under 2025 Incentive Plan

CONMED Corporation's Director Mark Kaye was granted 8,061 stock options and 668 restricted stock units under the company's 2025 Long-Term Incentive Plan.

Summary

• Mark Kaye, a Director of CONMED Corporation (CNMD), was granted equity awards on June 2, 2025.
• He received 8,061 options to purchase common stock with an exercise price of $55.38 per share.
• These options generally vest 100% after one year, on June 2, 2026, and have an expiration date of June 2, 2035.
• Additionally, Mr. Kaye was granted 668 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of common stock.
• The RSUs also generally vest 100% after one year, on June 2, 2026, or immediately upon termination of the Director's service.
• Both the stock options and RSUs were granted under the Company's 2025 Long-Term Incentive Plan.

Sentiment

Score: 7

Explanation: This Form 4 reports routine equity compensation for a director, which is a standard practice to align interests with shareholders. It does not contain information that would significantly alter the company's financial outlook or operations, thus indicating a neutral to slightly positive sentiment.

Positives

• The equity grants align the director's financial interests with the long-term performance and shareholder value creation of CONMED Corporation.
• The use of a formal Long-Term Incentive Plan demonstrates a structured approach to executive and director compensation, promoting retention and performance incentives.

Future Outlook

The grants are part of the company's 2025 Long-Term Incentive Plan, indicating a strategic focus on long-term performance and the retention of key personnel through equity-based compensation, with vesting schedules extending one year into the future.

Management Comments

• "The stock options were granted under the Company's 2025 Long-Term Incentive Plan and generally vest 100% after a one year period."
• "Each restricted stock unit ('RSU') represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the 'Company') and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period with the RSU vesting immediately upon termination of the Director's service."

Industry Context

Equity grants to directors and executives are a standard practice in the medical technology and healthcare industry, serving to align management incentives with shareholder interests and promote long-term retention. CONMED operates in the medical device sector, where attracting and retaining experienced leadership is crucial for innovation and market competitiveness.

Comparison to Industry Standards

• Equity compensation, including stock options and restricted stock units, is a common component of director compensation packages across publicly traded companies, particularly in the medical technology sector.
• The one-year vesting period for these grants is a typical structure designed to encourage continued service and align interests with long-term company performance.
• While specific comparable companies or projects are not detailed in this filing, similar compensation structures are observed at peers like Stryker Corporation, Zimmer Biomet Holdings, and Medtronic plc.

Corporate Governance

Related Party Transactions

• This filing details equity compensation granted by CONMED Corporation to Mark Kaye, a Director of the company, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The grants are designed to align the director's interests with shareholder value creation, as the value of the options and RSUs is directly tied to the company's stock performance. Potential minor dilution from future share issuance upon exercise/vesting is a consideration.
• Employees: No direct impact on general employees is mentioned in this specific filing.

Next Steps

• The granted stock options and Restricted Stock Units are scheduled to vest on June 2, 2026, subject to the terms of the 2025 Long-Term Incentive Plan.
• Upon vesting, the director will be able to exercise the options and receive shares for the RSUs.

Key Dates

Keywords

CONMED Corporation, CNMD, SEC Form 4, Insider transaction, Stock options, Restricted Stock Units, RSUs, Equity compensation, Director compensation, Long-Term Incentive Plan, Mark Kaye